Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

The global drug discovery services market is projected to grow at a CAGR of 15% from 2025 to 2030. This growth is driven by the increasing demand for outsourced drug discovery activities, advancements ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Top largecap stocks that mutual funds bought in June included Asian Paints, Trent, Bajaj Finserv, Infosys, and Bharti Airtel, ...

Indian market closed with a positive bias, as BSE Sensex and Nifty50 saw gains, led by auto, FMCG, realty, and IT sectors. Biocon, RBL Bank, and HDFC AMC hit fresh 52-week highs. Analysts suggest ...

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, ...

Fundraising through qualified institutional placements (QIPs) saw a revival in June after a tepid first five months of 2025, ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...